allogeneic islet

PreclinicalSmall molecule

SShanghai Changzheng Hospital

allogeneic islet is one of 3 small molecule programs targeting Islet Transplantation. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Islet TransplantationRecruiting

Islet TransplantationPreclinical

Recruiting

Competition

Competitive Landscape

2 competitors in Islet Transplantation

#DrugCompanyPhaseTrials

Allogenic Human Islet Cells

CCity of Hope Medical Center

Phase 2

1 2

Gastrin 17

CCity of Hope Medical Center

Phase 2

1 3

allogeneic islet

SShanghai Changzheng Hospital

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

N/ARecruiting

Islet Transplantation

NCT06751199

Clinical

Trials by Indication[1]

Islet Transplantation1 trial

UCMSCs Combined With Allogeneic Islet Transplantation for the Treatment of Diabetes

Recruiting·SShanghai Changzheng Hospital·N/A·NCT06751199·16 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for allogeneic islet. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — allogeneic islet compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for allogeneic islet. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shanghai Changzheng Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: SShanghai Changzheng Hospital

allogeneic islet

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Islet Transplantation1 trial

References

Drug Info

Quick Facts

Related News